{"organizations": [], "uuid": "23ba213d8954b150be610e6881435647b7c6bd05", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tetraphase-pharma-enters-exclusive/brief-tetraphase-pharma-enters-exclusive-development-and-commercialization-agreement-with-everest-medicines-idUSFWN1QA0YE", "country": "US", "domain_rank": 408, "title": "BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.503, "site_type": "news", "published": "2018-02-21T05:09:00.000+02:00", "replies_count": 0, "uuid": "23ba213d8954b150be610e6881435647b7c6bd05"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tetraphase-pharma-enters-exclusive/brief-tetraphase-pharma-enters-exclusive-development-and-commercialization-agreement-with-everest-medicines-idUSFWN1QA0YE", "ord_in_thread": 0, "title": "BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines", "locations": [], "entities": {"persons": [{"name": "eik", "sentiment": "none"}, {"name": "everest", "sentiment": "none"}], "locations": [{"name": "singapore", "sentiment": "none"}, {"name": "south korea", "sentiment": "none"}, {"name": "hong kong", "sentiment": "none"}], "organizations": [{"name": "everest medicines feb", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "tetraphase pharmaceuticals inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Tetraphase Pharmaceuticals Inc:\n* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA\n* TETRAPHASE PHARMACEUTICALS - WILL RECEIVE INITIAL UPFRONT PAYMENT OF $7.0 MILLION, MAY RECEIVE CLINICAL AND REGULATORY MILESTONES OF UP TO $16.5 MILLION\n* TETRAPHASE PHARMA-CO ‍MAY RECEIVE CLINICAL, REGULATORY MILESTONES OF UP TO $16.5 MILLION AS WELL AS ANNUAL SALES MILESTONES OF UP TO $20.0 MILLION​\n* TETRAPHASE PHARMACEUTICALS - ‍EVEREST WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT & COMMERCIALIZATION OF ERAVACYCLINE IN TERRITORIES​\n* TETRAPHASE PHARMACEUTICALS-CO, EVEREST TO ESTABLISH JOINT STEERING COMMITTEE TO REVIEW, OVERSEE ALL OF EVEREST‘S DEVELOPMENT, COMMERCIALIZATION PLANS\n* TETRAPHASE PHARMACEUTICALS - TO BE ELIGIBLE TO RECEIVE DOUBLE DIGIT TIERED ROYALTIES ON NET SALES OF ERAVACYCLINE IN AREAS UNDER AGREEMENT\n* TETRAPHASE PHARMA - ENTERED AGREEMENT WITH EVEREST MEDICINES TO DEVELOP, COMMERCIALIZE ERAVACYCLINE IN HONG KONG, SOUTH KOREA, SINGAPORE, AMONG OTHERS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T05:09:00.000+02:00", "crawled": "2018-02-21T21:19:28.021+02:00", "highlightTitle": ""}